Translational advances in pancreatic ductal adenocarcinoma therapy

AN Hosein, SK Dougan, AJ Aguirre, A Maitra - Nature cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy

S Bärthel, C Falcomatà, R Rad, FJ Theis, D Saur - Nature cancer, 2023 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …

[HTML][HTML] Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

JH Strickler, H Satake, TJ George… - New England journal …, 2023 - Mass Medical Soc
Abstract Background KRAS p. G12C mutation occurs in approximately 1 to 2% of pancreatic
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …

[HTML][HTML] Pancreatic cancer in 2021: What you need to know to win

V Tonini, M Zanni - World Journal of Gastroenterology, 2021 - ncbi.nlm.nih.gov
Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions

RT Lawlor, P Mattiolo, A Mafficini, SM Hong… - Cancers, 2021 - mdpi.com
Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …

Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age

PJ Trivedi, H Crothers, J Mytton, S Bosch, T Iqbal… - Gastroenterology, 2020 - Elsevier
Background & Aims There are insufficient population-level data on the effects of primary
sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD). Methods We …

Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems

S Marletta, N Fusco, E Munari, C Luchini… - Journal of Personalized …, 2022 - mdpi.com
Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

Facts and hopes in immunotherapy of pancreatic cancer

B Bockorny, JE Grossman, M Hidalgo - Clinical Cancer Research, 2022 - AACR
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to
treat. For patients with advanced and metastatic disease, chemotherapy has yielded only …

Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes

A Di Federico, M Mosca, R Pagani, R Carloni, G Frega… - Cancers, 2022 - mdpi.com
Simple Summary In pancreatic cancer, immunotherapy and targeted therapies have not
brought about the therapeutic revolution that has been observed in other malignancies …

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

C Luchini, G Paolino, P Mattiolo, ML Piredda… - Journal of Experimental …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait
is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases …